Endocrine therapy, commonly used to treat estrogen receptor–positive and progesterone receptor–positive breast cancers, and HER2-targeted therapies, used to treat HER2-positive breast cancers, are ineffective against TNBC. This evidence concerns the gene ESR1 and breast carcinoma.